摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基[1,3]恶唑并[4,5-d]嘧啶 | 129249-41-8

中文名称
2-甲基[1,3]恶唑并[4,5-d]嘧啶
中文别名
——
英文名称
2-methyloxazolo<4,5-d>pyrimidine
英文别名
2-Methyloxazolo[4,5-d]pyrimidine;2-methyl-[1,3]oxazolo[4,5-d]pyrimidine
2-甲基[1,3]恶唑并[4,5-d]嘧啶化学式
CAS
129249-41-8
化学式
C6H5N3O
mdl
MFCD18801054
分子量
135.125
InChiKey
CTANASBIJLHKQH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    222.4±13.0 °C(Predicted)
  • 密度:
    1.320±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    51.8
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:f6ff8380e160143b4f7b690bc314d2b3
查看

反应信息

  • 作为产物:
    参考文献:
    名称:
    新型杂环的合成:恶唑并[4,5-b]嘧啶和恶唑并[4,5-d]嘧啶
    摘要:
    通过将适当的邻羟基氨基嗪与原甲酸乙酯缩合,可制得新的嘌呤等位异构体(标题化合物)。延伸到其他原酸酯和硫代乙酰氨基乙酸苄酯可得到这些新的稠合杂环的2-烷基取代的衍生物。
    DOI:
    10.1016/s0040-4039(00)88750-x
点击查看最新优质反应信息

文献信息

  • SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
    申请人:BlinkBio, Inc.
    公开号:US20170202970A1
    公开(公告)日:2017-07-20
    Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.
    本文描述了基于硅的共轭物,能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心,一个或多个可选的催化基团,一个定位基团,允许共轭物在靶细胞或组织内积累,一个或多个有效载荷基团(例如,治疗剂或成像剂),以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
  • OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY
    申请人:Masuda Koji
    公开号:US20120253040A1
    公开(公告)日:2012-10-04
    Disclosed is a compound which is useful as an endothelial lipase inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is aromatic carbocycle or aromatic heterocycle, Z is —NR 5 —, —O— or —S—, R 5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or the like, R 1 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, R 2 and R 3 are each independently hydrogen, halogen, hydroxy or the like, R 4 is a group represented by the formula: —(CR 6 R 7 )n-R 8 , wherein R 6 and R 7 are each independently hydrogen, halogen, hydroxy or the like, n is an integer of 0 to 3, R 8 is carboxy, cyano, substituted or unsubstituted alkyl or the like, R x is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, m is an integer of 0 to 3.
    揭示了一种作为内皮酶抑制剂有用的化合物。 一种由下式表示的化合物: 其药学上可接受的盐,或其溶剂化合物, 其中 环A是芳香碳环或芳香杂环, Z是-NR 5 —,-O-或-S-, R 5 是氢,取代或未取代的烷基,取代或未取代的烯基,取代或未取代的炔基,取代或未取代的芳基或类似物, R 1 是氢,卤素,羟基,氰基,硝基,羧基,取代或未取代的烷基,取代或未取代的烯基或类似物, R 2 和R 3 各自独立地是氢,卤素,羟基或类似物, R 4 是由下式表示的基团:-(CR 6 R 7 )n-R 8 , 其中R 6 和R 7 各自独立地是氢,卤素,羟基或类似物,n是0到3的整数,R 8 是羧基,氰基,取代或未取代的烷基或类似物, R x 是卤素,羟基,氰基,硝基,羧基,取代或未取代的烷基,取代或未取代的烯基或类似物, m是0到3的整数。
  • [EN] PYRIDINIUM DERIVATIVES AS HERBICIDES<br/>[FR] DÉRIVÉS DE PYRIDINIUM EN TANT QU'HERBICIDES
    申请人:SYNGENTA CROP PROTECTION AG
    公开号:WO2021110890A1
    公开(公告)日:2021-06-10
    Compounds of the formula (I) (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
    化合物的化学式(I)(I),其中取代基如权利要求书中所定义,作为杀虫剂特别是除草剂时有用。
  • Syntheses of Oxazolo [4,5-<i>b</i>]pyridines and [4,5-<i>d</i>]pyrimidines
    作者:Muriel Doise、Dominique Blondeau、Henri Sliwa
    DOI:10.1080/00397919208021112
    日期:1992.11
    Abstract Oxazolo [4, 5-b] pyridines and [4, 5-d] pyrimidines and their 2-substituted compounds have been prepared respectively by condensation of orthoesters or thioimidates derivatives with 2-amino-3-hydroxypyridine and 4-amino-5-hydroxypyrimidine.
    摘要 通过原酸酯或硫代亚胺酯衍生物与 2-氨基-3-羟基吡啶和 4-氨基-5 缩合分别制备了恶唑并 [4, 5-b] 吡啶和 [4, 5-d] 嘧啶及其 2-取代化合物。 -羟基嘧啶。
  • Polymerisation Catalyst
    申请人:Gibson Vernon Charles
    公开号:US20080200625A1
    公开(公告)日:2008-08-21
    A polymerisation catalyst comprising (1) a transition metal compound of Formula (A), and optionally (2) an activator, wherein Z is 5-membered heterocyclic containing carbon, nitrogen and at least one other selected from nitrogen, sulphur and oxygen, the remaining atoms in the ring being nitrogen and carbon; M is a metal from Group 3 to 11 or a lanthanide metal; E 1 and E 2 are divalent hydrocarbon, heterocyclic or heterosubstituted derivatives of these; D 1 and D 2 are donor atoms or groups; X is an anionic group, L is a neutral donor group; n=m=zero or 1; y and z are zero or integers so that X and L satisfy the valency/oxidation state of M, characterized in that the complex contains at least one polymerisable olefinic double bond which is present in, or substituent to, at least one of the atoms, groups or ligands represented by Z, E, D and L. The catalyst binds to the forming polymer providing product with good particle morphology.
    一种聚合催化剂,包括(1)式(A)的过渡金属化合物,以及可选的(2)活化剂,其中Z是含有碳、氮和至少一种从氮、硫和氧中选择的其他元素的5元杂环,环中其余原子为氮和碳;M是3到11组或镧系金属中的金属;E1和E2是二价的碳氢化合物、杂环或这些的杂基衍生物;D1和D2是给体原子或基团;X是负离子基团,L是中性给体基团;n=m=0或1;y和z为零或整数,以使X和L满足M的化合价/氧化态,其特征在于该配合物至少含有一个聚合性烯烃双键,该双键存在于Z、E、D和L所代表的原子、基团或配体中的至少一个中或代替其中之一。催化剂与形成的聚合物结合,提供具有良好颗粒形态的产品。
查看更多